In a new study, researchers found a single dose of the flu drug baloxavir marboxil can reduce the spread of the illness within households.
Baloxavir marboxil, sold under the brand name Xofluza, was effective in adults, children and those at high-risk, regardless of whether they had received the flu vaccine.
The research was conducted by a team at the University of Virginia.
The team examined 752 household contacts of 545 patients with the flu found that flu infections were much less common in household members who received the drug than among those who received a placebo.
Only 1.9% of uninfected household contacts who took a single dose of baloxavir marboxil came down with the flu, compared with 13.6% of those who received the placebo.
The frequency of adverse events, such as headaches and nausea, was similar among those who received the drug (22.2%) and those who received placebos (20.5%). There were no deaths in either group.
The study shows that baloxavir, if taken within a day or so after exposure, is highly effective for preventing influenza illness in households, a high-risk setting for virus transmission.
The findings indicate that baloxavir prophylaxis should prove effective for prevention in other circumstances, such as outbreaks in nursing homes and healthcare facilities, although formal studies will need to be undertaken.
Previous research showed that baloxavir treatment shortened the duration of influenza and reduced complications in adults and adolescents at high risk of complications.
A single dose of the drug was as effective as a five-day course of oseltamivir (Tamiflu).
The federal Food and Drug Administration has approved baloxavir marboxil to treat flu within 2 days of symptom onset in people 12 years and older and those at high risk of developing complications.
Its approval in 2018 marked the first novel flu drug in 20 years. The FDA is reviewing baloxavir applications for both treatment in children aged 1-11 years and for prophylaxis.
One author of the study is Frederick G. Hayden, MD, of the University of Virginia School of Medicine.
The study is published in the New England Journal of Medicine.
Copyright © 2020 Knowridge Science Report. All rights reserved.
